Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
MoonLake Immunotherapeutics is a biotech company focused on developing Nanobody-based therapies for inflammatory skin and joint diseases. Its lead product, SLK, targets IL-17A and IL-17F to treat conditions like hidradenitis suppurativa, psoriatic arthritis, and psoriasis. The company advances clinical trials, seeks regulatory approval, and aims for commercialization, leveraging proprietary technology, strategic licensing, and partnerships to address unmet medical needs in immunology.
This description was generated via AI from an annual report. Updated about 1 year ago.